Clinical results analyze dexamethasone implant effect on macular thickness

Video
Conference|ARVO

Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Dr. Daniel F. Kiernan, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.

See more ARVO coverage

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
A woman with neck pain and glasses at a computer. Concept image for dry eye and fibromyalgia. Image credit: ©peopleimages.com – stock.adobe.com

Association between dry eye, ophthalmic structures and fibromyalgia syndrome

Lynda Charters
March 26th 2025
Article

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The Moorfields Eye Hospital NHS Foundation Trust logo courtesy NHS Foundation Trust. Insitro logo courtesy Insitro. Lock and data point assets created with Canva.

Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro

Hattie Hayes
March 24th 2025
Article

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Rows of medical syringes in sanitary packaging. Concept image for aflibercept intravitreal eye injection. ©Titolino – stock.adobe.com

Study examines real-world treat-and-extend outcomes and background factors of macular atrophy

Lynda Charters
March 21st 2025
Article

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

Researchers raise awareness of macular pathologies which mimic AMD and GA

Lynda Charters
March 20th 2025
Article

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

© 2025 MJH Life Sciences

All rights reserved.